Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.13B | 1.13B | 1.14B | 1.18B | 1.00B | 852.49M |
Gross Profit | 352.12M | 361.63M | 334.15M | 331.76M | 274.45M | 263.63M |
EBITDA | 254.64M | 265.40M | 250.22M | 224.24M | 189.70M | 194.79M |
Net Income | 139.89M | 149.46M | 148.13M | 128.34M | 103.81M | 106.32M |
Balance Sheet | ||||||
Total Assets | 1.55B | 1.65B | 1.57B | 1.46B | 1.32B | 1.33B |
Cash, Cash Equivalents and Short-Term Investments | 356.03M | 497.26M | 541.87M | 398.67M | 377.46M | 495.35M |
Total Debt | 0.00 | 17.85M | 13.84M | 12.53M | 13.49M | 14.28M |
Total Liabilities | 221.47M | 363.21M | 187.82M | 223.71M | 205.96M | 165.57M |
Stockholders Equity | 1.29B | 1.25B | 1.35B | 1.20B | 1.08B | 1.13B |
Cash Flow | ||||||
Free Cash Flow | 57.35M | 58.14M | 151.81M | 28.11M | 48.52M | 104.51M |
Operating Cash Flow | 153.01M | 181.92M | 220.84M | 77.57M | 97.06M | 156.00M |
Investing Cash Flow | -95.67M | -123.77M | -69.03M | -49.46M | -48.54M | -51.50M |
Financing Cash Flow | -191.65M | -102.75M | -8.61M | -6.90M | -166.40M | -6.32M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | C$13.49B | 16.00 | 16.68% | 1.54% | 9.80% | 60.44% | |
74 Outperform | C$13.49B | 16.01 | 16.78% | 1.56% | 9.80% | 60.44% | |
69 Neutral | C$1.63B | 8.90 | 9.65% | 9.99% | -2.58% | 100.21% | |
69 Neutral | C$1.63B | 9.13 | 9.65% | 9.80% | -2.58% | 100.21% | |
68 Neutral | C$2.57B | 13.30 | 10.79% | 7.60% | 4.69% | 4.54% | |
63 Neutral | £1.76B | 11.18 | 4.65% | 3.23% | 0.46% | -42.18% | |
56 Neutral | C$917.39M | ― | -0.47% | 5.33% | 2.88% | 80.95% |
Winpak Ltd. has announced its new role as an authorized converter of DuPont™ Tyvek® healthcare packaging, enhancing its product offerings for medical device applications from its Winnipeg site. This collaboration with DuPont™ Tyvek® represents a significant advancement in sustainable packaging solutions, aligning with the healthcare industry’s growing demand for eco-friendly options, and is expected to strengthen Winpak’s market position and commitment to environmental responsibility.
The most recent analyst rating on (TSE:WPK) stock is a Buy with a C$55.00 price target. To see the full list of analyst forecasts on Winpak stock, see the TSE:WPK Stock Forecast page.
Winpak Ltd. reported a decline in net income for the second quarter of 2025, with earnings falling by 22.2% compared to the same period in 2024. The decrease was attributed to a significant drop in gross profit, reduced net finance income, and increased operating expenses, although foreign exchange gains provided a slight offset. The company’s earnings for the first half of 2025 also saw a decrease of 12.9% compared to the previous year, highlighting ongoing challenges in maintaining profitability.
The most recent analyst rating on (TSE:WPK) stock is a Hold with a C$50.00 price target. To see the full list of analyst forecasts on Winpak stock, see the TSE:WPK Stock Forecast page.
Winpak Ltd. announced the election of its board of directors at the Annual Meeting of Shareholders, with a significant 95.30 percent of outstanding shares voted. The election results reflect strong shareholder support, particularly for Kenneth P. Kuchma and Dayna Spiring, indicating confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (TSE:WPK) stock is a Hold with a C$50.00 price target. To see the full list of analyst forecasts on Winpak stock, see the TSE:WPK Stock Forecast page.